Congenital hepatic fibrosis (CHF) is a hereditary fibrocystic disease that can progress to portal hypertension and recurrent cholangitis requiring liver transplantation (LT). It can be associated with renal pathology and need for kidney transplantation (KT). We describe the clinical characteristics and outcomes of patients undergoing liver transplantation alone (LTA) and simultaneous liver-kidney transplantation (SLKT) for CHF using the Unites States Scientific Registry of Transplant Recipients. 197 patients who received LT for CHF between 2002 and 2018 were identified – 87 (44.2%) received SLKT, 110 (55.8%) received LTA. The 1-, 3-, and 5-year patient survival were 99.0%, 96.2%, and 94.6%. The 1-, 3-, and 5-year liver graft survival were 94.9%, 91.1%, and 89.6%. No significant differences in patient or liver graft survival were observed between the SLKT and LTA groups, or between pediatric and adult recipients. 53.3% of patients with CHF necessitating LT also have significant renal disease requiring KT. Kidney graft survival for isolated KT prior to LT were poorer compared to KT performed simultaneously or after LT. Both LTA and SLKT for CHF are associated with excellent long-term outcomes in pediatric and adult patients.
This article is protected by copyright. All rights reserved.